Terms: = Sarcomas AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
39 results:
1. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract] [Full Text] [Related]
2. A first-in-human, phase 1a dose-escalation study of the selective mek1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract] [Full Text] [Related]
3. Functional impact and targetability of
Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
[TBL] [Abstract] [Full Text] [Related]
4. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with mek1/2 inhibitor trametinib: a case report.
Jiang Y; Liu X; Lv DL; Zhao XL
Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588
[TBL] [Abstract] [Full Text] [Related]
5. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
6. Selective Oral mek1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP
Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315
[TBL] [Abstract] [Full Text] [Related]
7. Selective Oral mek1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
[TBL] [Abstract] [Full Text] [Related]
8. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract] [Full Text] [Related]
9. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
[TBL] [Abstract] [Full Text] [Related]
10. A case of recurrent histiocytic sarcoma with map2k1 pathogenic variant treated with the MEK inhibitor trametinib.
Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
[TBL] [Abstract] [Full Text] [Related]
11. mek162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Gong J; Chen Y; Yang L; Pillai R; Shirasawa S; Fakih M
Anticancer Res; 2017 Jun; 37(6):2831-2838. PubMed ID: 28551618
[TBL] [Abstract] [Full Text] [Related]
12. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
[TBL] [Abstract] [Full Text] [Related]
13. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract] [Full Text] [Related]
14. Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.
Lützen U; Zhao Y; Lucht K; Zuhayra M; Marx M; Cascorbi I; Culman J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):37-48. PubMed ID: 27664035
[TBL] [Abstract] [Full Text] [Related]
15. Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway.
Lagares-Tena L; García-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Huertas-Martínez J; Sáinz-Jaspeado M; Mateo-Lozano S; Rodríguez-Galindo C; Rello-Varona S; Herrero-Martín D; Tirado OM
Oncotarget; 2016 Aug; 7(35):56889-56903. PubMed ID: 27487136
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
Wood K; Hensing T; Malik R; Salgia R
JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract] [Full Text] [Related]
18. Intralipid decreases apolipoprotein M levels and insulin sensitivity in rats.
Zheng L; Feng Y; Shi Y; Zhang J; Mu Q; Qin L; Berggren-Söderlund M; Nilsson-Ehle P; Zhang X; Luo G; Xu N
PLoS One; 2014; 9(8):e105681. PubMed ID: 25144649
[TBL] [Abstract] [Full Text] [Related]
19. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract] [Full Text] [Related]
20. Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Su J; Zhang XC; An SJ; Zhong WZ; Huang Y; Chen SL; Yan HH; Chen ZH; Guo WB; Huang XS; Wu YL
Chin J Cancer; 2014 Jul; 33(7):346-50. PubMed ID: 24823994
[TBL] [Abstract] [Full Text] [Related]
[Next]
